Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602

Acta Oncologica

Volumn 51, Issue 7, 2012, Pages 944-947

  Penna, Giuseppa ^a   Allegra, Alessandro ^a   Romeo, Giuseppa ^b   Alonci, Andrea ^a   Cannavò, Antonino ^a   Russo, Sabina ^a   D'Angelo, Arianna ^a   Petrungaro, Annamaria ^a   Musolino, Caterina ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ENOXAPARIN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; LENALIDOMIDE; PREDNISOLONE;

ADULT; AGED; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; ERYTHEMA MULTIFORME; FEMALE; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HLA TYPING; HUMAN; LETTER; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG ERUPTIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; ITALY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; THALIDOMIDE;

EID: 84866373848     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.640347     Document Type: Letter

References (15)

1. French L, Prins C. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. Philadelphia PA: Elsevier; 2008. pp. 287-300.
2. Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: A retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol 2008;74:238-40. (Pubitemid 351918878)
3. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs-The EuroSCAR study. J Invest Dermatol 2008;128:35-44. (Pubitemid 350249390)
4. Quaglino P, Caproni M, Antiga E, Del Bianco E, Osella-Abate S, Savoia P, et al. Italian Group of Immunopathology. Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology. Dermatology 2007;214:296-304. (Pubitemid 46659011)
5. Pirmohamed M, Arbuckle JB, Bowman CE, Brunner M, Burns DK, Delrieu O, et al. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007;8:1661-91.
6. Chung WH, Hung SI. Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergol Int 2010;59:325-32.
7. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B?1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA Recommendations. Pharmacogenomics 2008;9:1543-6.
8. Sviggum H, Davis M, Rajkumar V, Dispensieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 2006; 142: 1298-302. (Pubitemid 44583279)
9. Castaneda CP, Brandenburg NA, Bwire R, Burton GH, Zeldis JB. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J Clin Oncol 2009;27:156-7.
10. Allegra A, Alonci A, Penna G, Russo G, Gerace D, Greve B, et al. Steven-Johnson syndrome after Lenalidomide therapy for multiple myeloma: A case report and a review of treatment options. Hematol Oncol Epub 2011 Jun 23. doi: 10.1002/hon.1000.
11. Nakamura Y. Pharmacogenomics and drug toxicity. N Eng J Med 2008;359:856-8.
12. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, et al. Hypersensitivity reactions to carbamazepine: Characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003; 63:732-41. (Pubitemid 36297347)
13. Ueta M, Tokunaga K, Sotozono C, Inatomi T, Yabe T, Matsushita M, et al. HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vis 2008;14:550-5. (Pubitemid 351472356)
14. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, et al. A marker for Stevens-Johnson syndrome.: Ethnicity matters. Pharmacogenomics J 2006;6:265-8.
15. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18: 99-107.